Biocon posted a strong performance for Q4FY15 despite the exceptional income of Rs.105 crore via sale of shares in Syngene, its R&D arm. Consolidated net profit showed a jump of a whopping 122% at Rs.201 crore. And PBT before exceptional income rose 32% at Rs.143 crore.

Overall it has been a good operational performance, with total income going up 15% at Rs.830 crore with biopharma, which contributes 71% to the topline, showing a 11% rise, led by biopharma growing 12% and branded formulations in India rose 6%. Contract research  rose 27%. EBITDA came in at Rs.202 crore, up 5%. Currently it has no interest outgo.

The company, last week filed its DRHP for Syngene with SEBI and an IPO is expected in the next couple of months. It will be offering shares through an offer for sale (OFS) route. Upto 22 million equity shares of face value of Rs 10 each will be offered for cash and at such premium as may be determined. The offer includes a reservation of 2 million equity shares for Biocon shareholders.

Currently the stock is up 3% at Rs.455.75, with an intra day high and low of Rs.460.15 and Rs.449.40 respectively. Its 52-week high is at Rs.553.70.